News

Exosome Diagnostics Completes $20 Million Series A Financing

NEW YORK, May 11, 2010 – Exosome Diagnostics, Inc. today announced it has raised $20 million co-led by NGN Capital ("NGN"), New York, and Forbion Capital Partners ("Forbion"), Naarden, The Netherlands, to further develop and commercialize a series of next-generation body fluid based oncology diagnostics through its proprietary, exosome based technology platform. More…